Table 2.
Hematologic and Hemolytic Parameters Before and After Hematopoietic Stem Cell Transplantation Among 26 Engrafted Patients
| Reference Range | Mean (95% CI) | |||||
|---|---|---|---|---|---|---|
| Pre-HSCT (n = 30) |
Exchange (n = 30)a |
6 Month (n = 26) |
1 Year (n = 26) |
Most Recent (n = 23) |
||
| Hemoglobin | ||||||
| Women | ||||||
| g/dL | 11.2–15.7 | 8.1 (7.3–8.9) | 8.8 (8.4–9.3) | 10.8 (9.8–11.8) | 11.9 (11.2–12.6) | 12.7 (11.8–13.6) |
| g/L | 112–157 | 81 (73–89) | 88 (84–93) | 108 (98–118) | 119 (112–126) | 127 (118–136) |
| Men | ||||||
| g/dL | 13.7–17.5 | 8.9 (8.4–9.3) | 9.3 (8.8–9.7) | 12.0 (10.9–13.2) | 12.1 (11.0–13.3) | 13.7 (12.3–15.1) |
| g/L | 137–175 | 89 (84–93) | 93 (88–97) | 120 (109–132) | 121 (110–133) | 137 (123–151) |
| Lactate dehydrogenase | ||||||
| U/L | 113–226 | 324 (272–375) | 305 (253–358) | 239 (211–267) | 198 (179–217) | 202 (182–221) |
| µkat/L | 1.7–3.4 | 5.4 (4.5–6.3) | 5.1 (4.2–6.0) | 4.0 (3.5–4.5) | 3.3 (3.0–3.6) | 3.4 (3.0–3.7) |
| Total bilirubin | ||||||
| mg/dL | 0.1–1.0 | 2.7 (1.7–3.7) | 2.7 (1.5–4.0) | 0.7 (0.5–0.9) | 0.7 (0.3–1.0) | 0.9 (0.4–1.5) |
| µmol/L | 5–21 | 46.2 (29.4–62.9) | 46.9 (25.6–68.1) | 12.2 (9.1–15.3) | 11.6 (5.6–17.5) | 15.8 (6.4–25.2) |
| Reticulocyte | ||||||
| 109 cells/L | 16–78 | 182 (145–220) | 136 (106–166) | 84 (64–105) | 76 (54–98) | 85 (53–117) |
| Homozygous hemoglobin S, % | ||||||
| Sickle trait donors | 35–41 | 63.7 (52.9–74.4) | 33.0 (29.4–36.7) | 31.5 (25.3–37.8) | 35.3 (30.6–40.1) | 39.8 (35.1–44.4) |
| Normal adult hemoglobin donors | 0 | 56.2 (30.4–81.9) | 22.3 (14.6–30.0) | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) |
a
Pre-HSCT denotes approximately 1 month before hematopoietic stem cell transplant (HSCT); exchange, after red cell exchange procedure; 6 mo, 6 mo after HSCT; 1 year, 1 year after HSCT; and most recent, at the most recent follow-up (median, 3.6 years; range, 1.0–8.4).